XNAS
ELUT
Market cap15mUSD
Jul 09, Last price
0.97USD
1D
2.32%
1Q
-13.98%
IPO
-31.72%
Name
Aziyo Biologics Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Aziyo Biologics, Inc. (AZYO) operates as a regenerative medicine firm, concentrating its efforts on developing advanced medical products. Their primary applications target three key areas: implantable electronic devices and cardiovascular care, orthopedic and spinal repair, and the reconstruction of soft tissues. The company's product portfolio includes CanGaroo, an innovative envelope that incorporates antibiotics, specifically engineered to lower the risk of infection following the surgical implantation of an electronic device. Aziyo also provides a suite of cardiovascular solutions. ProxiCor serves as an intracardiac patch or pledget for repairing heart tissues, while Tyke is designed for neonates and infants to mend pericardial structures. Additionally, VasCure offers a versatile patching material for the repair or reconstruction of peripheral blood vessels, encompassing critical arteries like the carotid, renal, iliac, femoral, and tibial, serving cardiovascular, vascular, and general surgeons. For orthopedic procedures, Aziyo offers human tissue-derived bone allografts such as Fiber VBM, ViBone, and OsteGro V. These products are formulated to protect and preserve the body's natural bone cells. In the realm of soft tissue repair, they feature SimpliDerm, a pre-hydrated human acellular dermal matrix (HADM) developed for the repair or replacement of damaged or insufficient skin and related integumental tissues. Beyond its proprietary product line, Aziyo Biologics extends contract manufacturing services, producing various items for other corporate clients. The company distributes its products to hospitals and other healthcare facilities through a multi-faceted sales approach, utilizing its dedicated direct sales force, strategic commercial partners, and independent sales agents. Founded in 2015, Aziyo Biologics, Inc. maintains its headquarters in Silver Spring, Maryland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||